Endostatin improves cancer-associated systemic syndrome in a lung cancer model

Wang,Xia; Zhan,Rui‑Yu; Wang,Yu‑Yi; Yan,Xi; Cao,Dan; Li,Yan; Wang,Yi‑Qin; Luo,Feng

doi:10.3892/ol.2015.3049

Endostatin improves cancer-associated systemic syndrome in a lung cancer model

Authors:
- Xia Wang
- Rui‑Yu Zhan
- Yu‑Yi Wang
- Xi Yan
- Dan Cao
- Yan Li
- Yi‑Qin Wang
- Feng Luo
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/ol.2015.3049
Pages: 2023-2030
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer-associated systemic syndrome (CASS) is characterized by a constellation of symptoms, including progressive weight loss, anemia, endocrine disorders, gastrointestinal dysfunction, muscle and adipose atrophy, hepatic peliosis and kidney failure. The present study assesses the effects of endostatin on CASS and any possible underlying mechanism in tumor‑bearing mice. The results showed that the inoculation of Lewis lung carcinoma cells into mice led to CASS that was characterized by a notable decrease in body weight, severe anemia phenotype, disordered biochemistry, hepatosplenomegaly, and a marked increase in serum vascular endothelial growth factor (VEGF), tumor necrosis factor α and interleukin‑6 (IL‑6). The continuous injection of 10 mg/kg/day endostatin suppressed tumor growth and alleviated CASS in the tumor‑bearing mice, as shown by weight gain, improvement in biochemistry and anemia, and the preservation of organ function. The effects of endostatin on CASS in the tumor‑bearing mice were accompanied by the downregulation of serum VEGF and IL‑6. Collectively, these findings indicate that endostatin improves CASS in tumor‑bearing mice by decreasing the serum levels of VEGF and IL-6.

View Figures

View References

1	Nathanson L and Hall TC: Introduction: paraneoplastic syndromes. Semin Oncol. 24:265–268. 1997.PubMed/NCBI
2	Nakamura I, Shibata M, Gonda K, et al: Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
3	Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer. 2:862–871. 2002. View Article : Google Scholar : PubMed/NCBI
4	Inui A: Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 52:72–91. 2002. View Article : Google Scholar : PubMed/NCBI
5	Takahashi Y, Yasumoto K and Mai M: Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy. Oncol Rep. 14:135–140. 2005.PubMed/NCBI
6	Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al: Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem. 40:1353–1360. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 104:17069–17074. 2007. View Article : Google Scholar : PubMed/NCBI
8	Xue Y, Religa P, Cao R, et al: Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA. 105:18513–18518. 2008. View Article : Google Scholar : PubMed/NCBI
9	Cao Y: Off-tumor target - beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol. 7:604–608. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Zhang J, Jiang D, et al: Inhibition of T-type Ca²⁺ channels by endostatin attenuates human glioblastoma cell proliferation and migration. Br J Pharmacol. 166:1247–1260. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lim J, Duong T, Lee G, et al: The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. Biomaterials. 34:6261–6271. 2013. View Article : Google Scholar : PubMed/NCBI
13	Xu W, Ye P, Li Z, et al: Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells. Mol Biol (Mosk). 44:664–670. 2010. View Article : Google Scholar : PubMed/NCBI
14	Huszthy PC, Brekken C, Pedersen TB, et al: Antitumor efficacy improved by local delivery of species-specific endostatin. J Neurosurg. 104:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhang X, Yang G, Zhang Y, et al: An experimental research into endostatin microbubble combined with focused ultrasound for anti-tumor angiogenesis in colon cancer. Gastroenterol Rep (Oxf). 2:44–53. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ning T, Jiang M, Peng Q, et al: Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. Thoracic Cancer. 3:229–238. 2012. View Article : Google Scholar
17	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kayacan O, Karnak D, Beder S, et al: Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol. 29:328–335. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yang Q, Wan L, Zhou Z, et al: Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma. Phytomedicine. 20:992–998. 2013. View Article : Google Scholar : PubMed/NCBI
20	Noguchi Y, Makino T, Yoshikawa T, et al: The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations. Surg Today. 26:36–41. 1996. View Article : Google Scholar : PubMed/NCBI
21	Barton BE and Murphy TF: Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 16:251–257. 2001. View Article : Google Scholar : PubMed/NCBI
22	Liu S, Wu HJ, Zhang ZQ, et al: L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Cancer Biol Ther. 12:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kamba T, Tam BY, Hashizume H, et al: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 290:H560–H576. 2006. View Article : Google Scholar : PubMed/NCBI
24	Rein DT, Volkmer AK, Volkmer J, et al: Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. Oncol Lett. 3:530–534. 2012.PubMed/NCBI